PMOS: Kaletra Tolerability
Phase of Trial: Phase IV
Latest Information Update: 26 May 2017
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Non-nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms PMOS
- Sponsors Abbott Laboratories; AbbVie
- 07 Jun 2017 Biomarkers information updated
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 May 2015 Planned number of patients changed from 3000 to 3200, according to ClinicalTrials.gov record.